<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609231</url>
  </required_header>
  <id_info>
    <org_study_id>0646-025</org_study_id>
    <secondary_id>2012-000317-36</secondary_id>
    <nct_id>NCT01609231</nct_id>
  </id_info>
  <brief_title>A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)</brief_title>
  <official_title>A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this adaptive trial is to compare the progression-free survival of
      participants with metastatic rectal carcinoma when treated with dalotuzumab + irinotecan
      therapy relative to participants treated with cetuximab + irinotecan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From randomization (Cycle 1 Day 1) to the first documented disease progression or death due to any cause, whichever occurs first (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>From randomization (Cycle 1 Day 1) to the first documented disease progression or death due to any cause, whichever occurs first (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A: Dalotuzumab + Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Cetuximab + Irinotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalotuzumab</intervention_name>
    <description>Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.</description>
    <arm_group_label>Arm A: Dalotuzumab + Irinotecan</arm_group_label>
    <other_name>MK-0646</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 180 mg/m^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator, such as with dexamethasone or atropine will follow local, or country-specific standard of care.</description>
    <arm_group_label>Arm A: Dalotuzumab + Irinotecan</arm_group_label>
    <arm_group_label>Arm B: Cetuximab + Irinotecan</arm_group_label>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m^2 followed by weekly infusions of 250 mg/m^2. Pre-medication at the discretion of the investigator, such as with a histamine receptor antagonist or corticosteroid, will follow local, or country-specific standard of care.</description>
    <arm_group_label>Arm B: Cetuximab + Irinotecan</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic colorectal cancer with primary tumor originating from the

        rectum

          -  Available archival (recent or remote) tumor, or newly obtained formalin-fixed tissue
             available for analysis for biomarker studies

          -  At least one measurable lesion greater than or equal to 10 mm

          -  Disease has progressed after treatment with both irinotecan and oxaliplatin

        containing regimens and should have progressed on or within 3 months of completing their
        last line of therapy

          -  Performance status 0-1 on the Eastern Cooperative Oncology Group (ECOG) Performance
             Scale

        Exclusion Criteria:

          -  Known diabetic who is poorly controlled

          -  Chemotherapy or biological therapy within 2 weeks prior to initial dosing on this
             study, or whose toxicities from agents administered 2 weeks earlier have not resolved
             to at least grade 1 or baseline, or who is within 3 weeks from

        a prior surgery

          -  Radiotherapy within 2 weeks prior to initial dosing on this study, unless the
             radiotherapy was for management of pain

          -  Currently participating or has participated in a study with an investigational
             compound or device within 30 days or 5 half-lives of the investigational agent,
             whichever is longer, of initial dosing on this study

          -  Could not complete previous course of irinotecan due to intolerable toxicity, other
             than discontinuation due to fatigue following prolonged administration (&gt;4 months
             exposure)

          -  Prior exposure to insulin-like growth factor 1 receptor (IGF-1R) inhibitors or
             epidermal growth factor receptor (EGFR) inhibitors

          -  Known Central Nervous System (CNS) metastases and/or carcinomatous meningitis

          -  Primary CNS tumor

          -  History of a prior malignancy with the exception of cervical intraepithelial
             neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate
             carcinoma; potentially curative therapy with no evidence of that disease for 5 years,
             deemed low risk for recurrence by treating physician.

          -  Human Immunodeficiency Virus (HIV)-positive

          -  Active Hepatitis B or C receiving antiviral treatment regimens

          -  Symptomatic ascites or pleural effusion

          -  Concurrently using growth hormone (GH), or growth hormone inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2012</study_first_submitted>
  <study_first_submitted_qc>May 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

